WallStreetZenWallStreetZen

NASDAQ: RADX
Radiopharm Theranostics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RADX

Based on 3 analysts offering 12 month price targets for Radiopharm Theranostics Ltd

Min Forecast
$12.00+139.04%
Avg Forecast
$15.00+198.8%
Max Forecast
$18.00+258.57%

Should I buy or sell RADX stock?

Based on 3 analysts offering ratings for Radiopharm Theranostics Ltd.

Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RADX stock forecasts and price targets.

RADX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-21
lockedlocked$00.00+00.00%2025-05-01
lockedlocked$00.00+00.00%2025-03-12

1 of 1

Forecast return on equity

Is RADX forecast to generate an efficient return?

Company
-12,598.61%
Industry
71.62%
Market
-18.68%
RADX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RADX forecast to generate an efficient return on assets?

Company
-7,249.92%
Industry
23.88%
RADX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RADX earnings per share forecast

What is RADX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.01
Avg 2 year Forecast
-$3.51
Avg 3 year Forecast
-$1.94

RADX revenue forecast

What is RADX's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$880.0k-15.81%
Avg 2 year Forecast
$1.3M+25.33%
RADX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RADX revenue growth forecast

How is RADX forecast to perform vs Biotechnology companies and vs the US market?

Company
11.25%
Industry
222.03%
Market
11.61%
RADX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RADX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RADX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RADX$5.02$15.00+198.80%Strong Buy
CASI$2.17$4.00+84.33%Buy
IGC$0.37$3.88+944.47%Strong Buy
RNXT$0.92$7.25+687.19%Buy
RANI$0.55$7.33+1,235.70%Strong Buy
View Top Biotech Stocks

Radiopharm Theranostics Stock Forecast FAQ

Is Radiopharm Theranostics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: RADX) stock is to Strong Buy RADX stock.

Out of 3 analysts, 3 (100%) are recommending RADX as a Strong Buy, 0 (0%) are recommending RADX as a Buy, 0 (0%) are recommending RADX as a Hold, 0 (0%) are recommending RADX as a Sell, and 0 (0%) are recommending RADX as a Strong Sell.

If you're new to stock investing, here's how to buy Radiopharm Theranostics stock.

What is RADX's earnings growth forecast for 2025-2027?

(NASDAQ: RADX) Radiopharm Theranostics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.6%.

Radiopharm Theranostics's earnings in 2025 is -$25,688,349.On average, 1 Wall Street analyst forecast RADX's earnings for 2025 to be -$21,729,608, with the lowest RADX earnings forecast at -$21,729,608, and the highest RADX earnings forecast at -$21,729,608. On average, 2 Wall Street analysts forecast RADX's earnings for 2026 to be -$7,627,092,254, with the lowest RADX earnings forecast at -$8,431,087,733, and the highest RADX earnings forecast at -$6,823,096,774.

In 2027, RADX is forecast to generate -$4,215,543,867 in earnings, with the lowest earnings forecast at -$4,215,543,867 and the highest earnings forecast at -$4,215,543,867.

What is RADX's revenue growth forecast for 2025-2026?

(NASDAQ: RADX) Radiopharm Theranostics's forecast annual revenue growth rate of 11.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 222.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.61%.

Radiopharm Theranostics's revenue in 2025 is $1,058,411.On average, 1 Wall Street analysts forecast RADX's revenue for 2025 to be $1,912,205,465, with the lowest RADX revenue forecast at $1,912,205,465, and the highest RADX revenue forecast at $1,912,205,465.

In 2026, RADX is forecast to generate $2,846,578,590 in revenue, with the lowest revenue forecast at $2,846,578,590 and the highest revenue forecast at $2,846,578,590.

What is RADX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: RADX) forecast ROA is -7,249.92%, which is lower than the forecast US Biotechnology industry average of 23.88%.

What is RADX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RADX price target, the average RADX price target is $15.00, with the highest RADX stock price forecast at $18.00 and the lowest RADX stock price forecast at $12.00.

On average, Wall Street analysts predict that Radiopharm Theranostics's share price could reach $15.00 by Jul 21, 2026. The average Radiopharm Theranostics stock price prediction forecasts a potential upside of 198.8% from the current RADX share price of $5.02.

What is RADX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RADX) Radiopharm Theranostics's current Earnings Per Share (EPS) is -$12.13. On average, analysts forecast that RADX's EPS will be -$0.01 for 2025, with the lowest EPS forecast at -$0.01, and the highest EPS forecast at -$0.01. On average, analysts forecast that RADX's EPS will be -$3.51 for 2026, with the lowest EPS forecast at -$3.88, and the highest EPS forecast at -$3.14. In 2027, RADX's EPS is forecast to hit -$1.94 (min: -$1.94, max: -$1.94).

What is RADX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: RADX) forecast ROE is -12,598.61%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.